LUBAC: a new player in polyglucosan body disease
| Autor: | Sharmistha Mitra, Andrew Aboujaoude, Berge A. Minassian |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
HOIP
Cardiomyopathy Biochemistry Molecular Bases of Health & Disease chemistry.chemical_compound ubiquitin ligases Mice Ubiquitin LUBAC medicine Animals Humans Myopathy HOIL-1L Review Articles Glucans Immunodeficiency Post-Translational Modifications Glycogen biology Molecular Interactions Molecular Structure Neurodegeneration Ubiquitination Signal transducing adaptor protein M1 ubiquitination medicine.disease Therapeutics & Molecular Medicine gene therapy Protein ubiquitination Cell biology Metabolism chemistry biology.protein medicine.symptom Signal Transduction |
| Zdroj: | Biochemical Society Transactions |
| ISSN: | 1470-8752 0300-5127 |
| Popis: | Altered protein ubiquitination is associated with the pathobiology of numerous diseases; however, its involvement in glycogen metabolism and associated polyglucosan body (PB) disease has not been investigated in depth. In PB disease, excessively long and less branched glycogen chains (polyglucosan bodies, PBs) are formed, which precipitate in different tissues causing myopathy, cardiomyopathy and/or neurodegeneration. Linear ubiquitin chain assembly complex (LUBAC) is a multi-protein complex composed of two E3 ubiquitin ligases HOIL-1L and HOIP and an adaptor protein SHARPIN. Together they are responsible for M1-linked ubiquitination of substrates primarily related to immune signaling and cell death pathways. Consequently, severe immunodeficiency is a hallmark of many LUBAC deficient patients. Remarkably, all HOIL-1L deficient patients exhibit accumulation of PBs in different organs especially skeletal and cardiac muscle resulting in myopathy and cardiomyopathy with heart failure. This emphasizes LUBAC's important role in glycogen metabolism. To date, neither a glycogen metabolism-related LUBAC substrate nor the molecular mechanism are known. Hence, current reviews on LUBAC's involvement in glycogen metabolism are lacking. Here, we aim to fill this gap by describing LUBAC's involvement in PB disease. We present a comprehensive review of LUBAC structure, its role in M1-linked and other types of atypical ubiquitination, PB pathology in human patients and findings in new mouse models to study the disease. We conclude the review with recent drug developments and near-future gene-based therapeutic approaches to treat LUBAC related PB disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|